NOVADAQ to Release Third Quarter 2016 Financial Results on November 2, 2016—Conference Call to Follow
October 20 2016 - 4:45PM
NOVADAQ Technologies Inc. ("NOVADAQ" or the “Company")
(NASDAQ:NVDQ) (TSX:NDQ), the leading developer and provider of
clinically relevant fluorescence imaging solutions for use in
surgical and diagnostic procedures, will announce financial results
for the third quarter of 2016 after market close on Wednesday,
November 2, 2016.
NOVADAQ President and Chief Executive Officer,
Rick Mangat and Chief Financial Officer, Roger Deck, will host a
conference call at 4:30 p.m. ET to review the financial results and
discuss business developments in the period.
Q3 2016 Results Conference Call
Details:
Date: |
Wednesday, November 2, 2016 |
Time: |
4:30 p.m. ET |
Live Call: |
1-866-320-0174 within Canada and
the United States (U.S.) |
|
1-785-424-1631 outside of Canada
and the U.S. |
Replay: |
1-877-481-4010 within Canada and
the U.S. |
|
1-919-882-2331 outside of Canada
and the U.S. |
|
Replay ID: 10122 |
The call will also be broadcast live and
archived on the Company's website at novadaq.com under the "Events"
tab in the Investor's section. A replay of the call will be
available for download to a portable audio player or computer, as
an MP3 or podcast file, at the same location on NOVADAQ's
website.
About NOVADAQ Technologies
Inc.
NOVADAQ’s global mission is to enable physicians
with point-of-care imaging solutions that provide real time
clinically significant and actionable information to improve care
quality and lower healthcare costs. Using NOVADAQ’s SPY
fluorescence imaging technology, physicians can personalize therapy
and achieve optimal results through the precise visualization of
blood flow in vessels, micro-vessels, tissue perfusion and critical
anatomical structures during the course of treatment. SPY
technology enables the delivery of personalized therapies and the
achievement of the optimal results for each individual patient.
More than 220 peer-reviewed publications demonstrate that the use
of SPY technology will reduce post-procedure complication rates and
the cost of care for a broad variety of surgical treatments for
cancer, cardiovascular diseases and other conditions, helping to
ensure that patients benefit from the very best possible treatment
and outcome.
SPY Imaging Systems are U.S. Food and Drug
Administration 510(k) cleared, Health Canada licensed, CE Marked
and registered worldwide for use in multiple surgical specialties
and medical applications. The endoscopic version of SPY technology,
known as PINPOINT, combines the fluorescence imaging capabilities
of SPY with the high definition visible light visualization to
establish a new standard in the quality and performance of
minimally invasive surgery. NOVADAQ’s LUNA System is used to
visualize blood flow and tissue perfusion while treating patients
with atherosclerotic cardiovascular disease that impairs blood flow
to the extremities and increases the risk for the development of
complications such as acute and chronic non-healing wounds and limb
loss. NOVADAQ is the exclusive worldwide distributor of LifeNet
Health’s DermACELL acellular tissue products for wound and breast
reconstruction surgery.
Forward-Looking Statements
Certain statements included in this press
release may be considered forward-looking. Such statements involve
known and unknown risks, uncertainties and other factors that may
cause actual results, performance or achievements to be materially
different from those implied by such statements, and therefore
these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on
NOVADAQ’s current beliefs as well as assumptions made by and
information currently available to NOVADAQ and relate to, among
other things, the Company’s strategy, strategic goals, research and
development activities, research and clinical testing outcomes,
taxes, capital expenditures, future operations, future financial
position, future revenues/results, projected costs, prospects and
plans and objectives of management.
Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release. Due to risks and uncertainties,
including the risks and uncertainties identified by NOVADAQ in its
public securities filings available at www.sec.gov and
www.sedar.com, actual events may differ materially from current
expectations. NOVADAQ disclaims any intention or obligation to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
NOVADAQ, SPY, PINPOINT, LUNA and the
illumination square design are registered trademarks of Novadaq
Technologies Inc. LifeNet Health and DermACELL are registered
trademarks of LifeNet Health.
For more information, please contact:
Roger Deck
Chief Financial Officer
1-905-629-3822 ext. 206
rdeck@novadaq.com
Novadaq Technologies (NASDAQ:NVDQ)
Historical Stock Chart
From Aug 2024 to Sep 2024
Novadaq Technologies (NASDAQ:NVDQ)
Historical Stock Chart
From Sep 2023 to Sep 2024